 |
54 Diseases |  |
8 Trials |
|
8 Trials |  |
2662 News |  |
| «12...1112131415161718192021...2324» |
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: Administration of crushed ledipasvir-sofosbuvir tablets via gastrostomy button in a patient coinfected with HIV and hepatitis C virus. (Pubmed Central) - May 30, 2019
No abstract available
- | Copegus (ribavirin) / Bausch Health, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal, Real-World Evidence: Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. (Pubmed Central) - May 30, 2019
No abstract available SOF/LDV with or without RBV for 8-24 weeks is well tolerated and achieves a high SVR12 rate in patients with HCV-1 infection in Taiwan.
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1. (Pubmed Central) - May 30, 2019
A multivariable logistic regression model including age, sex, liver stiffness, G1 subtype, HCV-RNA, HIV, and treatment duration showed the factors associated with treatment failure to be male sex (adjusted odds ratio [aOR], 2.49; 95% confidence interval [CI], 1.27-4.91; P = .008) and HIV infection (aOR, 2.23; 95% CI, 1.13-4.38; P = .020). The results of this large prospective study analyzing outcomes for LDV/SOF against HCV G1 in treatment-naïve noncirrhotic patients suggest that HIV infection is a predictor of treatment failure in patients with chronic hepatitis C.
- | paritaprevir/ritonavir (ABT-450/r) / AbbVie, daclatasvir/asunaprevir (BMS-60032/BMS-790052) / BMS
Journal: Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C. (Pubmed Central) - May 29, 2019
Both older and younger patients respond similarly to DAA therapy. Advanced liver fibrosis affects the virological response to sofosbuvir-based therapy.
- | daclatasvir/sofosbuvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New trial: Effect of Direct AntiViral Drugs of Chronic HCV on eGFR in Assuit Universiry Hospital (clinicaltrials.gov) - May 28, 2019
P, N=80, Not yet recruiting, Sponsor: Assiut University
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: Remission of CIDP after hepatitis C virus eradication with sofosbuvir and ledipasvir therapy. (Pubmed Central) - May 26, 2019
Advanced liver fibrosis affects the virological response to sofosbuvir-based therapy. No abstract is available for this article.
- | tenofovir / ScinoPharm Taiwan, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Observational data, Journal: Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study. (Pubmed Central) - May 24, 2019
We observed a significant decrease in eGFR during treatment in all study groups, that was small and reversible after SOF/LDV discontinuation. TDF was not associated with an increase in renal toxicity.
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
But big ups to @GileadSciences for curing my Hep-C. Get tested. #Harvoni (Twitter) - May 23, 2019
- | ledipasvir/sofosbuvir / Generic mfg.
New P4 trial: Hyalornic Acid Level in ?-Thalassemic Children Treated for Hepatitis C Virus (clinicaltrials.gov) - May 22, 2019
P4, N=50, Completed, Sponsor: Tanta University
- | Sovaldi (sofosbuvir) / Gilead, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
@GileadSciences can I get the profit you make from one Harvoni or Sovaldi treatment? I'd like a 90k windfall. K thanks. (Twitter) - May 22, 2019
- ||| Cimivir-L (sofosbuvir+ledipasvir) / Gilead
HEOR: Cost effectiveness of treating #HepatitisC in #Seychelles #SIDS #Africa #Hepatitis #Harvoni @GHirnschall @MargaretHellard @GileadSciences https://t.co/qV5FzEqzoo (Twitter) - May 15, 2019
- ||| ledipasvir/sofosbuvir / Generic mfg.
Trial completion, Adherence: Evaluation of HepCure Toolkit to Improve Harvoni Adherence (clinicaltrials.gov) - May 13, 2019
P=N/A, N=71, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
TDF was not associated with an increase in renal toxicity. Recruiting --> Completed
- | Reyataz (atazanavir sulfate) / BMS
Clinical, Journal: Favorable outcome with direct acting antiviral treatment in hepatitis C patients coinfected with human immunodeficiency virus. (Pubmed Central) - May 12, 2019
DAA treatment for patients coinfected with HCV/HIV is as effective as in patients infected only with HCV. It was generally well tolerated except one patient who discontinued the treatment due to severe headache.
- | pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
Clinical, Journal: High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients. (Pubmed Central) - May 9, 2019
DAA-related adverse events were rare. Interferon-free DAA regimens (including 34% pan-genotypic regimens) yielded 100% SVR12 in HIV/AHC individuals if treatment durations similar to CHC are applied.
- | Daklinza (daclatasvir) / BMS
Clinical, Journal: Transjugular Intrahepatic Portosystemic Shunt: A Possible Risk Factor for Direct-Acting Antiviral Treatment Failure in Patients With Hepatitis C? (Pubmed Central) - May 8, 2019
We observed a high rate of virological relapse in patients with a TIPS who received DAA treatment and therefore postulate that TIPS placement may be a possible risk factor for DAA failure due to the profound hemodynamic changes evoked by the intervention. Longer treatment duration or addition of ribavirin might be warranted in these patients.
- | Copegus (ribavirin) / Bausch Health, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Journal: Treatment of HCV in the Department of Corrections in the Era of Oral Medications. (Pubmed Central) - May 7, 2019
Multiple logistic regression of GT1 patients identified lower FIB-4 ( p = .008) and treatment clinic ( p = .01) as independent predictors of SVR12. HCV treatment in the DOC by telemedicine with DAA is not only feasible but has a very high SVR12 similar to published trials.
- | Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie, Daklinza (daclatasvir) / BMS
Clinical, Observational data, Journal: Hepatitis C treatment with all-oral direct-acting antivirals: Effectiveness and tolerance in a multicenter, prospective, observational study from French general hospitals (APROVVIE, ANGH). (Pubmed Central) - May 6, 2019
Second generation DAAs combinations are as effective and well tolerated in a « real-world » population as in clinical trials. Further studies are needed on renal tolerance.
- | Sunvepra (asunaprevir) / BMS, paritaprevir/ritonavir (ABT-450/r) / AbbVie, Daklinza (daclatasvir) / BMS
Retrospective data, Review, Journal: Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: systematic review and meta-analysis. (Pubmed Central) - May 5, 2019
Further studies are needed on renal tolerance. Direct-acting antiviral treatment is highly effective and well-tolerated in liver transplant recipients with recurrent GT1 HCV infection.
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: A Randomized Controlled Trial of Cash Incentives or Peer Support to Increase HCV Treatment for Persons With HIV Who Use Drugs: The CHAMPS Study. (Pubmed Central) - May 4, 2019
P=N/A
...All participants received 12-weeks of ledipasvir/sofosbuvir (LDV/SOF)...Research involving PLWH who use drugs should focus on overcoming barriers to treatment initiation. The registration data for the trial are in the ClinicalTrials.gov database, number NCT02402218.
- | Daklinza (daclatasvir) / BMS
Clinical, Journal: Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents. (Pubmed Central) - May 1, 2019
Immune changes that follow HCV clearance might lead to reactivation of other viruses, such as herpesvirus. Patients with HCV infection suspected of having herpesvirus infection should be treated promptly.
- | NN1213 / Novo Nordisk
Trial completion: Extrahepatic Insulin Resistance in Chronic Hepatitis C (clinicaltrials.gov) - May 1, 2019
P=N/A, N=17, Completed, Sponsor: University Hospital, Geneva
Patients with HCV infection suspected of having herpesvirus infection should be treated promptly. Active, not recruiting --> Completed
- ||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment change, Trial completion date, Trial primary completion date: APOSTLE: Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection (clinicaltrials.gov) - May 1, 2019
P2, N=25, Recruiting, Sponsor: University of Maryland
Active, not recruiting --> Completed N=10 --> 25 | Trial completion date: Nov 2019 --> Feb 2020 | Trial primary completion date: May 2019 --> Nov 2019
- |||| Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical: If curing hepatitis C cost what it costs to MAKE a curative dose of harvoni, the perceived risk to the health system of treating every case would be trivial. I think that we would see a lot less of this discussion. (Twitter) - Apr 30, 2019
- | Sovaldi (sofosbuvir) / Gilead
Retrospective data, Review, Journal: Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis. (Pubmed Central) - Apr 30, 2019
Our study suggests SOF-based regimen might be used safely and effectively in patients living with HCV infection/stage 4-5 CKD, with normal and reduced dose of sofosbuvir. Prospective and well-controlled trials are needed to confirm these findings.
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Gilead make $13.8 gazillion per year on Harvoni lonely (Twitter) - Apr 27, 2019
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Gilead make $13.8 billion per yr on Harvoni only (Twitter) - Apr 27, 2019
- | Copegus (ribavirin) / Bausch Health, daclatasvir/asunaprevir (BMS-60032/BMS-790052) / BMS, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study. (Pubmed Central) - Apr 26, 2019
Prospective and well-controlled trials are needed to confirm these findings. Ledipasvir/sofosbuvir with ribavirin is an effective retreatment option for patients with chronic hepatitis C who failed to respond to prior daclatasvir and asunaprevir therapy.
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Sovaldi (sofosbuvir) / Gilead, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Vosevi Works Well as #HepatitisC Salvage Treatment by @benryanwriter https://t.co/62jRRWboA8 @GileadSciences #EASL2019 #Epclusa #Harvoni #salvagetherapy #Sovaldi #Vosevi (Twitter) - Apr 25, 2019
- | Copegus (ribavirin) / Bausch Health, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation. (Pubmed Central) - Apr 24, 2019
In HCV positive recipients, DAA regimens are highly effective and safe. A significant decrease of LS by transient elastography and fibrosis non-invasive scores can be observed after successful therapy.
- | Olysio (simeprevir) / J&J, Medivir, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment. (Pubmed Central) - Apr 24, 2019
A significant decrease of LS by transient elastography and fibrosis non-invasive scores can be observed after successful therapy. Treatment with LDV/SOF with/without RBV for 12-24 weeks was very well tolerated and resulted in high SVR 12 rates (96%) in HCV GT1 relapsers to SMV + SOF treatment.
- NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia (clinicaltrials.gov) - Apr 23, 2019
P2/3, N=10, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Treatment with LDV/SOF with/without RBV for 12-24 weeks was very well tolerated and resulted in high SVR 12 rates (96%) in HCV GT1 relapsers to SMV + SOF treatment. Trial completion date: Dec 2018 --> Apr 2019 | Trial primary completion date: Dec 2018 --> Apr 2019
- || Sovaldi (sofosbuvir) / Gilead, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Vosevi Works Well as #HepatitisC Salvage Treatment by @benryanwriter https://t.co/62jRRWboA8 @GileadSciences #EASL2019 #Epclusa #Harvoni #salvagetherapy #Sovaldi #Vosevi (Twitter) - Apr 20, 2019
- || Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
Enrollment closed: A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection (clinicaltrials.gov) - Apr 19, 2019
P=N/A, N=1637, Active, not recruiting, Sponsor: Gilead Sciences
Trial completion date: Dec 2018 --> Apr 2019 | Trial primary completion date: Dec 2018 --> Apr 2019 Enrolling by invitation --> Active, not recruiting
- | Daklinza (daclatasvir) / BMS
Clinical, Journal: Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, with Chronic Hepatitis C Infection. (Pubmed Central) - Apr 19, 2019
This data could provide support to our suggested response-tailored protocol of dual therapy with SOF/DCV in adolescents particularly for shortened duration in those who achieved vRVR. Further larger randomized controlled studies are recommended.
- | Copegus (ribavirin) / Bausch Health, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: Treatment of Chronic Hepatitis C Virus Infection in Children. A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. (Pubmed Central) - Apr 19, 2019
Further larger randomized controlled studies are recommended. This position paper addresses therapeutic management issues including goals, endpoints, indications, contra-indications and the optimal treatment regimen in children with chronic HCV infection.
- | Olysio (simeprevir) / J&J, Medivir, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy. (Pubmed Central) - Apr 18, 2019
This position paper addresses therapeutic management issues including goals, endpoints, indications, contra-indications and the optimal treatment regimen in children with chronic HCV infection. In line with the findings of the OPTIMIST-2 trial for Q80K and the EASL-guidelines 2016 for NS5A-RASs, baseline RASs appeared to have an impact on treatment outcome albeit a statistical significance was not observed in this low-prevalence population.
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Review, Journal: Novel NS5B Resistance-Associated Substitution Emerges Under Failing Sofosbuvir/Ledipasvir Therapy. (Pubmed Central) - Apr 18, 2019
In line with the findings of the OPTIMIST-2 trial for Q80K and the EASL-guidelines 2016 for NS5A-RASs, baseline RASs appeared to have an impact on treatment outcome albeit a statistical significance was not observed in this low-prevalence population. No abstract available
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Journal: Blistering Disease During the Treatment of Chronic Hepatitis C With Ledipasvir/Sofosbuvir. (Pubmed Central) - Apr 16, 2019
No abstract available Hepatitis C virus-associated porphyria cutanea tarda can result from viral-induced inhibition of uroporphyrinogen decarboxylase and the subsequent accumulation of uroporphyrins and associated metabolites in urine.
- || Sovaldi (sofosbuvir) / Gilead, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Vosevi Works Well as #HepatitisC Salvage Treatment by @benryanwriter https://t.co/62jRRWboA8 @GileadSciences #EASL2019 #Epclusa #Harvoni #salvagetherapy #Sovaldi #Vosevi (Twitter) - Apr 15, 2019
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Journal: Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy. (Pubmed Central) - Apr 13, 2019
In this large real-world cohort, PWID and/or those on OAT achieved high SVRs, although slightly lower than people not injecting drugs. This finding also highlights the need for additional measures to prevent loss to follow-up and overdose-related deaths among PWID.
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population. (Pubmed Central) - Apr 12, 2019
This finding also highlights the need for additional measures to prevent loss to follow-up and overdose-related deaths among PWID. Our results suggest that direct-acting antivirals, particularly ledipasvir/sofosbuvir, are generally effective for achieving SVR among underserved patients with HCV infections and may help reduce inequalities in HCV prevalence and outcomes for this vulnerable population.
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal, Real-World Evidence: Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C. (Pubmed Central) - Apr 12, 2019
There is a significant rate of noncompliance among patients treated with DAA in real-world clinical practice despite pre-treatment education efforts. The ITT-SVR rates observed in clinical practice were significantly lower than those reported by clinical trials, and this difference was most pronounced among treatment-naïve patients.
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Retrospective data, Journal: Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL. (Pubmed Central) - Apr 12, 2019
The ITT-SVR rates observed in clinical practice were significantly lower than those reported by clinical trials, and this difference was most pronounced among treatment-naïve patients. Eight-week LDV/SOF therapy in treatment-naive, non-cirrhotic, genotype 1 HCV patients with RNA < 6 million IU/mL was found safe, better tolerated, effective, and required less upfront cost when compared with the 12-week LDV/SOF treatment regimen in properly selected geriatric population.
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal, HEOR: Health-Related Quality of Life in Adolescent Patients with Hepatitis C Genotype 1 Treated with Sofosbuvir and Ledipasvir. (Pubmed Central) - Apr 11, 2019
Treatment of HCV in adolescents with LDV/SOF is associated with some improvement in HRQL. Caregivers' reports of HRQL in adolescents with HCV significantly increased with treatment and were similar to the adolescent self-reported HRQL after SVR-12.
- | Copegus (ribavirin) / Bausch Health, Olysio (simeprevir) / J&J, Medivir, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Journal: No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk. (Pubmed Central) - Apr 11, 2019
There are no significant differences between DAA regimens in HCC risk after antiviral treatment. This suggests that DAAs do not have direct carcinogenic effects as it would be unlikely that different DAAs would have identical carcinogenic effects.
- || Cimivir-L (sofosbuvir+ledipasvir) / Gilead
yeah that's a good point, i agree here. given how expensive harvoni is, i think it would need to be made clear.... 1 shot at public drug benefit. thoughts ? (Twitter) - Apr 9, 2019
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients. (Pubmed Central) - Apr 7, 2019
An 8-week regimen of LDV/SOF was well tolerated and efficacious in this treatment-naïve, non-cirrhotic HCV GT4-infected population. This study provides valuable information on a short treatment regimen for HCV GT4 infection in a real-world setting.
- | sofosbuvir/velpatasvir/voxilaprevir (GS-7977/GS-5816/GS-9857) / Gilead, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Journal: Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification. (Pubmed Central) - Apr 6, 2019
Despite the presence of polymorphisms at resistance-associated substitution positions, 18 of the 19 patients treated with sofosbuvir-containing therapy achieved SVR12. Nineteen novel HCV subtypes were identified, suggesting an even greater genetic diversity of HCV subtypes than previously recognized.
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: Association Between Baseline Creatinine Clearance and Treatment Failure in Patients With Hepatitis C Virus Treated With Ledipasvir and Sofosbuvir. (Pubmed Central) - Apr 6, 2019
In the multivariate analysis, pretreatment creatinine clearance >80 mL min-1 remained independently associated with SVR12 failure (odds ratio, 2.95; 95% confidence interval, 1.17-7.46; P = .023). In hepatitis C patients treated with LDV/SOF, a pretreatment creatinine clearance of >80 mL min-1 was associated with SVR12 failure.
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: Effectiveness of Direct-Acting Antiviral Therapy in Patients With Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter Study. (Pubmed Central) - Apr 6, 2019
...Cirrhosis (fibrosis-4 index>3.25) was present in 24%, and 17% were interferon treatment experienced; 96% had genotype 1 infection and 432 (81%) had received ledipasvir-sofosbuvir...Our study represents a large multicenter examination of DAA therapy in HIV/HCV-coinfected patients. The broad treatment success we observed across this diverse group of patients with significant comorbid conditions is highly affirming and argues for widespread implementation of DAA therapy.